Group items tagged

A recent study presented at the European Congress on Obesity in Venice sheds light on the detrimental effects of obesity on workplace absenteeism and economic productivity. The analysis, encompassing data from millions of workers across Europe, reveals a direct correlation between body mass index (BMI) and the likelihood of taking sick leave. According to the study, obese individuals are up to twice as likely to take time off work due to health issues compared to those of a healthy weight. The increased sick notes among obese individuals is attributed to various complications associated with obesity, including joint pain, diabetes, depression, and heart disease. In the United Kingdom, where obesity rates are among the highest in Europe, the impact of obesity on workplace absenteeism is particularly pronounced.

The Department of Health (DoH) is inviting the public to share their views on a new Regional Obesity Management Service and a new Obesity Strategic Framework. A public consultation has been launched on the Healthy Futures strategic framework, which aims to prevent the harm caused by obesity, and improve diets and levels of physical activity of people. The Department is also seeking views on its plans to introduce a new service that would focus on the introduction of specialist support, weight loss medication, and bariatric surgery to help people living with obesity. Northern Ireland is seeing an increase in obesity rates, with the latest Health Survey NI data showing that 65 per cent of adults and 26 per cent of children in the country are either obese or overweight.

The Lords Food, Diet and Obesity Committee has expressed disappointment with the government's response to its recommendations for tackling the obesity crisis. In October 2024, the Committee released its report, Recipe for Health: A Plan to Fix Our Broken Food System, following a special inquiry. The report identified obesity and diet-related diseases as a public health emergency, costing society billions annually in healthcare expenses and lost productivity. It urged the government to develop a "comprehensive, integrated long-term new strategy to fix the food system", supported by a new legislative framework and outlined key actions that should be included. The government published its response to the report on 30 January 2025, but the Committee criticized it for lacking boldness and delaying many necessary measures. Baroness Walmsley, who chaired the Committee said: "In recent interviews with researchers, former prime ministers and health secretaries expressed regret that they had not done more to tackle obesity and advised the government to 'be bold and act fast'. "The report from the Lords Food, Diet and Obesity Committee recommended bold measures to be implemented immediately.

No Junk food ads on television will be allowed before the 9 pm watershed from October 2025 under a new law. The UK government confirmed the final details of advertising restrictions, including a ban on paid online junk food adverts, on Tuesday (3 December). The proposed legislation is part of a broader strategy to curb childhood obesity and address rising rates of obesity-related diseases such as diabetes and heart disease. Detailed guidance on which food and drink categories will be covered by the regulations has also been published. These measures are expected to remove 7.2 billion calories per year from UK children's diets, potentially preventing around 20,000 cases of childhood obesity. Health secretary Wes Streeting emphasised the need for such preventative action, stating: "Obesity robs our kids of the best possible start in life, sets them up for a lifetime of health problems, and costs the NHS billions. "This government is taking action now to end the targeting of junk food ads at kids, across both TV and online.

मोटापा (Obesity) क्या है ? कारण, लक्षण और कम करने के उपाय | Motapa Obesity ? Causes, Symptoms and How to Reduce Obesity. - Health Tips - Tips to Weight Loss

Rachna Chhatralia, superintendent pharmacist at Day Lewis, has suggested that obesity should be a key focus area of the upcoming 10-year health plan. She advocated for a weight loss service to be commissioned through community pharmacies to address this growing public health issue effectively. "Obesity is a big problem in the UK, and it has progressively worsened as a result of COVID, with people being at home, unable to access gyms, and developing unhealthy eating habits," Rachna told Pharmacy Business. Rachna, the winner of the Pharmacy Business' Aspiring Pharmacy Leader of the Year, emphasised the urgent need to tackle obesity as it can lead to other long-term conditions in the long run and cost the NHS a lot of money. "If you don't try and tackle the obesity rate, you're then looking at treatment for other comorbidities, such as hypertension, diabetes, and cardiovascular issues, including heart attack and strokes. It just spirals out of control," she explained.

A roundtable organised by National Pharmacists Association (NPA) discussed how an enhanced role of community pharmacies could help people with obesity. Seven action points were recommended by the delegates at the virtual event which took place on March 31, in collaboration with Novo Nordisk. It was chaired by Professor Maggie Rae, president of the Faculty of Public Health and featured representatives from the Royal Pharmaceutical Society, Royal Society for Public Health, Patients Association, UK Health Security Agency, Diabetes UK and NHS England. The roundtable also heard testimony from a parent of a young adult living with obesity and a presentation of the personal experience of someone living with the condition by Sarah Le Brocq, director of campaign group, All About Obesity.

A new class of weight loss drugs developed by Novo Nordisk and Eli Lilly "opens the possibility of an end to the obesity pandemic" alongside other interventions, the World Health Organisation (WHO) said this week. But the global health agency said it has concerns that unless health systems prepare properly, the drugs could distort the response to the global obesity crisis, risking leaving people behind and overshadowing other steps to improve health. The new drugs "have the potential to be transformative", according to the WHO's chief scientist, Jeremy Farrar, its director of nutrition, Francesco Branca, and his senior adviser, Francesca Celleti, in an opinion piece in the Journal of the American Medical Association (JAMA). The article is the agency's clearest comment yet on the potential of the new drugs, known as GLP-1 receptor agonists. But "medication in isolation will not be enough to address the obesity crisis," they added, calling instead for the innovation to push clinicians, governments, the pharmaceutical industry and the public towards considering the condition a chronic disease that needs further study into how best to prevent and treat it.

Part of a raft of National Health Services (NHS) measures which aim to support people to prevent or reduce incidence of type 2 diabetes and obesity, the NHS Digital Weight Management Programme has emerged as a beacon of success in the battle against obesity, with a recent study showcasing its effectiveness in aiding weight loss among participants. According to research published in The Obesity Journal, the programme has garnered significant traction, with over 63,000 individuals referred in its inaugural year. Encouragingly, half of those referred opted to enroll in the service, highlighting its appeal and accessibility. Among the 14,000 participants who completed the 12-week programme between April 2021 and March 2022, a notable average weight loss of 3.9kg (equivalent to 8.59lbs) was achieved. Even among those who did not complete the programme, an average weight loss of 2.2kg (approximately 4.85lbs) was observed.

The best exercise for obese people is also one of the best exercises for anyone. Walking is a great exercise that most people can do. You can walk indoors or outdoors, with or without an expensive gym membership. Walking is one of the best ways to exercise for obese people, and it can make a big difference fast.

Today obesity is one of the most growing problems from health perspective. People use different kinds of medicines which instead of decreasing obesity harm their body. Acaifood provides best healthy solutions to get rid of it without using any kind of medicine. So don't waste time and visit acaifood.com for best possible solutions against obesity.

Germany's Boehringer Ingelheim said on Thursday (Aug 17) it would conduct three late-stage studies for its obesity drug candidate after it showed up to 19 per cent weight loss after 46 weeks in a mid-stage trial. The private company plans to start enrollments for the trial of the drug, survodutide, which it co-invented with Danish biotech company Zealand Pharma, before the end of the year. The trials will evaluate the drug's safety and efficacy, Boehringer said, and added that it would provide further details on the studies before initiation. Boehringer and Zealand are among global drugmakers racing to grab a share of the potential $100 billion market for obesity treatments within a decade. Survodutide works by mimicking a gut hormone called glucagon-like peptide-1 (GLP-1), which suppresses appetite, as well as imitating another gut hormone called glucagon that helps break down fat.

Amgen's experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday (December 3). The small Phase I trial found that patients maintained their weight loss for 70 days after receiving the highest tested dose of the injected drug, currently known as AMG133. Amgen shares have gained about 5% since the company said on Nov. 7 that 12 weeks of trial treatment at the highest monthly dose of AMG133 resulted in mean weight loss of 14.5%. At 150 days after the last dose, maintained weight loss had dropped to 11.2% below original weight at the start of the trial, according to findings detailed at a meeting of World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease in Los Angeles. Patients treated with AMG133 did have side effects including nausea and vomiting, but most cases were mild and resolved within a couple of days after the first dose, Amgen said.

Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online pharmacies say, in a sign the US drugmaker is gaining ground on its European rival. Mounjaro is appealing to people because of its greater efficacy, six online pharmacies and two patients told Reuters, showing Novo's first-mover advantage is being challenged in the UK even though some pharmacies sell starter doses for the weekly injection for up to 40 per cent more than Wegovy. "Mounjaro is now vastly outstripping Wegovy," said Chemist4U CEO James O'Loan, who said for the past three to four months, Mounjaro has won about 70 per cent of its sales. Chemist4U and another online seller, Simple Online Pharmacy, estimate that as many as 500,000 people in the UK currently take either Mounjaro or Wegovy via prescriptions from private online pharmacies. Mounjaro, unlike Wegovy, is not available through the National Health Service (NHS) though it likely will be next year. Wegovy is only available through the NHS at specialist obesity clinics and in limited circumstances. There is no public data on prescription numbers but the government said last year it had capacity to treat about 35,000 patients.

Obesity statistics in America amazes every one because of its extent and rapidity. Here are few shocking facts about the causes of obesity & overweight in children.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication of semaglutide (Wegovy), authorising its use to reduce the risk of serious heart problems and strokes in adults who are obese or overweight. Semaglutide, a GLP-1 receptor agonist, was previously approved for use in the treatment of obesity and weight management, to be used alongside diet, physical activity and behavioural support. The latest approval establishes it as the first weight loss drug to be prescribed to prevent cardiovascular events, such as cardiovascular death, non-fatal heart attack and non-fatal stroke, in people with established cardiovascular disease and a Body Mass Index (BMI) higher or equal to 27 kg/m2. Novo Nordisk, the manufacturer of Wegovy, received this authorisation on 23 July following compelling evidence from a recent post-approval clinical study involving over 17,600 participants. The study demonstrated that Wegovy, administered at a dose of 2.4 mg once weekly via subcutaneous injection for up to five years, significantly lowers the incidence of major adverse cardiovascular events (MACE) by 20 per cent compared to a placebo.

Obesity at teen-age is a big problem today. However, medicines are not best solution to prevent this. Instead taking proper and balanced diet is helpful to stop obesity. AcaiFood always tries to provide you best solutions to different diseases without using any medicine.

Being obese is very normal in our life! But do you know that it is very much harmful to our health. Obesity can cause various diseases like Type 2 Diabetes, Heart Diseases, Gallstones etc. It is a big problem which is..

Novo Nordisk, the Danish drug manufacturer, has launched Wegovy, a weight-loss drug, in the UK market. This semaglutide injection will be available through specialist NHS weight management services for those who meet the National Institute for Care and Excellence (NICE) criteria or privately through registered healthcare professionals. Novo Nordisk allocated a portion of the available supply of Wegovy for NHS services, while confirming the existing shortage of semaglutide and projecting continued constraints in the foreseeable future. The drug can be obtained through the NHS and is additionally accessible for private purchase at pharmacies in the UK. The pricing for a one-month supply varies, ranging from £73.25 to £175.80, depending on the dosage. "We are committed to expanding treatment options for individuals with obesity and share the Government's goal of improving access to obesity care in areas of high unmet medical need," the company said in a statement. "We are closely monitoring Wegovy demand and collaborating with regulators and providers to ensure access to and continuity of treatment for people living with obesity."